Gemcitabina [Inn-Spanish]
Gemcitabina [Inn-Spanish] Brand names, Gemcitabina [Inn-Spanish] Analogs
Gemcitabina [Inn-Spanish] Brand Names Mixture
- No information avaliable
Gemcitabina [Inn-Spanish] Chemical_Formula
C9H11F2N3O4
Gemcitabina [Inn-Spanish] RX_link
http://www.rxlist.com/cgi/generic/gemcitab.htm
Gemcitabina [Inn-Spanish] fda sheet
Gemcitabina [Inn-Spanish] msds (material safety sheet)
Gemcitabina [Inn-Spanish] Synthesis Reference
No information avaliable
Gemcitabina [Inn-Spanish] Molecular Weight
263.198 g/mol
Gemcitabina [Inn-Spanish] Melting Point
168.64oC
Gemcitabina [Inn-Spanish] H2O Solubility
Soluble
Gemcitabina [Inn-Spanish] State
Solid
Gemcitabina [Inn-Spanish] LogP
-1.318
Gemcitabina [Inn-Spanish] Dosage Forms
Lyophilized powder for injection
Gemcitabina [Inn-Spanish] Indication
For the first-line treatment of patients with metastatic breast cancer, locally advanced (Stage IIIA or IIIB), or metastatic (Stage IV) non-small cell lung cancer and as first-line treatment for patients with adenocarcinoma of the pancreas.
Gemcitabina [Inn-Spanish] Pharmacology
Gemcitabine is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA. They prevent these substances becoming incorporated in to DNA during the "S" phase (or DNA synthesis phase of the cell cycle), stopping normal development and division. Gemcitabine blocks an enzyme which converts the cytosine nucleotide into the deoxy derivative. In addition, DNA synthesis is further inhibited because Gemcitabine blocks the incorporation of the thymidine nucleotide into the DNA strand.
Gemcitabina [Inn-Spanish] Absorption
100%
Gemcitabina [Inn-Spanish] side effects and Toxicity
Myelosuppression, paresthesias, and severe rash were the principal toxicities, LD50=500 mg/kg (orally in mice and rats)
Gemcitabina [Inn-Spanish] Patient Information
General �� Patients receiving therapy with Gemzar should be monitored closely by a physician
experienced in the use of cancer chemotherapeutic agents. Most adverse events are reversible and
do not need to result in discontinuation, although doses may need to be withheld or reduced.
There was a greater tendency in women, especially older women, not to proceed to the next
cycle.
Laboratory Tests �� Patients receiving Gemzar should be monitored prior to each dose with a
complete blood count (CBC), including differential and platelet count. Suspension or
modification of therapy should be considered when marrow suppression is detected.
experienced in the use of cancer chemotherapeutic agents. Most adverse events are reversible and
do not need to result in discontinuation, although doses may need to be withheld or reduced.
There was a greater tendency in women, especially older women, not to proceed to the next
cycle.
Laboratory Tests �� Patients receiving Gemzar should be monitored prior to each dose with a
complete blood count (CBC), including differential and platelet count. Suspension or
modification of therapy should be considered when marrow suppression is detected.
Gemcitabina [Inn-Spanish] Organisms Affected
Humans and other mammals
![Gemcitabina_[Inn-Spanish]](/images/rx/APRD00201.gif)
